Kopran Valuation

Is KOPRAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KOPRAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KOPRAN (₹220.2) is trading above our estimate of fair value (₹55.06)

Significantly Below Fair Value: KOPRAN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KOPRAN?

Key metric: As KOPRAN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for KOPRAN. This is calculated by dividing KOPRAN's market cap by their current earnings.
What is KOPRAN's PE Ratio?
PE Ratio	20.1x
Earnings	₹528.93m
Market Cap	₹10.64b

KOPRAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	14x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does KOPRAN's PE Ratio compare to its peers?

The above table shows the PE ratio for KOPRAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	19.6x
506260 Anuh Pharma	16.9x	n/a	₹10.0b
531633 Lincoln Pharmaceuticals	12.8x	n/a	₹12.3b
524774 NGL Fine-Chem	26.9x	n/a	₹11.1b
506197 Bliss GVS Pharma	22x	n/a	₹13.9b
KOPRAN Kopran	20.1x	n/a	₹10.6b

Price-To-Earnings vs Peers: KOPRAN is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the peer average (19.6x).

Price to Earnings Ratio vs Industry

How does KOPRAN's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$69.15m
524652 Ind-Swift	2x	n/a	US$12.99m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: KOPRAN is good value based on its Price-To-Earnings Ratio (20.1x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is KOPRAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KOPRAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate KOPRAN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹294.55

-0.4%

-21.5%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Novartis India

₹25.4b

Operates as a healthcare company in India.

500672

₹1,027.80

-0.7%

47.3%